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i:10.1016/j.ejvs.2009.10.005Patients undergoing vascular surgery are prone to develop
perioperative cardiac events. Therefore, appropriate
preoperative cardiac risk assessment and implementation
of proper risk reduction strategies are of imminent impor-
tance. The recently published new guidelines of the Euro-
pean Society of Cardiology on perioperative cardiac care
provide valuable tools for daily clinical practice for the
vascular surgeon.1 In this editorial the most important
recommendations for elective vascular surgery patients are
highlighted (Fig. 1).
Preoperative Cardiac Risk Stratification
Step 1. Active cardiac disease
The first step in elective vascular surgery should be the
identification of active cardiac disease. This includes, for
example, unstable coronary artery disease and signs of a very
recent myocardial infarction. In this case the patient should
be referred immediately for evaluation of this active cardiac
condition to a cardiologist prior to surgery.
Step 2. Surgical risk
Patients undergoing vascular surgery are generally at greater
cardiac risk than patients undergoing any other type of
surgery. However, also in vascular surgery patients, there isty for Vascular Surgery. Publishea slight distinction between different procedures. For
example, carotid endarterectomy is considered to be a less
hazardous procedure compared with abdominal aortic
aneurysm repair or lower extremity arterial revascularisa-
tion procedures. The impact of endovascular procedures is
less well established, although it is generally accepted that
this type of procedures constitutes a less invasive and thus
less cardiac-demanding procedure. The new ESC guidelines
classify endovascular abdominal aortic aneurysm repair,
carotid artery endarterectomy and peripheral angioplasty as
intermediate-risk procedures.Step 3. Functional capacity
The new guidelines recommend assessment of functional
capacity in all patients undergoing intermediate or high-
risk surgery, that is, virtually all vascular surgery patients.
Patients who have a functional capacity of less than four
metabolic equivalents (METs) are at higher risk (Fig. 2). A
MET< 4 is equivalent to the inability to climb two flights of
stairs or run a short distance. Obviously for patients with
lower extremity arterial insufficiency, this might not always
be possible to assess. Vascular surgical patients with a good
functional capacity (MET> 4) might be scheduled for
surgery provided they are on statin therapy and low-dose
beta-blocker is initiated and appropriately titrated in the
perioperative period.
In patients with a low functional capacity, the cardiac
risk of the procedure should be considered. Patientsd by Elsevier Ltd. All rights reserved.
Figure 1 Flow chart of the new ESC guidelines for perioperative cardiac care.
2 Editorialscheduled for intermediate risk might be scheduled for
the procedure after an electrocardiogram (ECG) is per-
formed and appropriate medical therapy (i.e., statin,
low-dose titration of beta-blockers and angiotensin-con-
verting enzyme (ACE) inhibitors for those with systolicdysfunction) is initiated. For those with a low functional
capacity (MET< 4) scheduled for a high-risk procedure,
that is, open aortic or lower extremity arterial proce-
dures, the identification of cardiac risk factors is the next
step.
1 MET
Can you…
Greater than 10 METs
Take care of yourself 
Eat,dress, or use the toilet?
Walk indoors around the house?
Walk indoors around the house?
Walk 100 meters on level ground at 3 to 5 
km/h?
5 METs
4 METs
Climb 2 flights of stairs or walk uphill, run 
short distances?
Do heavy work around the house like 
scrubbing floors, or lifting or moving  
heavy furniture?
Participate in strenuous sports like 
swimming, singles tennis, football? 
Figure 2 Assessment of functional capacity using METs. One
MET equals the basic metabolic rate.
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Risk factors that should be taken into consideration are
a history of myocardial infarction, angina pectoris, diabetes
mellitus, renal dysfunction, a history of transient ischaemic
attack (TIA) or cerebrovascular accident (CVA) and
congestive heart failure. At each preoperative screening
visit, these clinical cardiac risk factors must be assessed
and taken into account in the decisions regarding appro-
priate cardiac work-up and cardioprotective medication
prescription in patients scheduled for major vascular
surgery. In patients with up to two clinical cardiac risk
factors (intermediate clinical cardiac risk), statins, low-
dose titration of beta-blockers should be initiated to all of
them prior to vascular surgery and ACE inhibitors for those
with systolic dysfunction. Additional cardiac stress testing
is not recommended in this patient group.
Step 5. Additional cardiac testing
The need for additional cardiac testing depends on the sum
of clinical cardiac risk factors and the type of vascular
surgery the patient is scheduled for. If patients have three
or more clinical risk factors and are scheduled for open
aortic surgery or open lower extremity arterial surgery
cardiac stress testing is recommended. In selected cases
one might also consider additional cardiac testing as means
of patient counselling. If cardiac stress testing shows no or
only mild stress-inducible myocardial ischaemia, additional
invasive testing is not recommended. Again, all patients
should be prescribed statins, low-dose titration of beta-
blockers prior to surgery and those with systolic dysfunction
should have additional ACE inhibitors.
Patients with extensive stress-inducible myocardial
ischaemia representa very difficult groupofpatients.Optimal
medical treatment includingbeta-blockers andstatinswill not
provide sufficient cardioprotection. However, also preopera-
tive prophylactic coronary revascularisation is not generallyassociated with improved perioperative outcome in this
patient population. An individualised approach should be
made for these patient taking into account the very high
cardiac risk of theplanned surgical procedureand thepossible
harms of not performing surgery (i.e., risk of rupture in AAA
patients). If it is decided to perform preoperative revascu-
larisation after multidisciplinary consultation, it must be
realised that the vascular surgical procedure must be post-
poned at least 14 days for balloon angioplasty, 3 months for
bare-metal coronary stent placement and 12months for drug-
eluting coronary stent placement.
Perioperative Medical Cardiac Risk Reduction
Statins
Statins play an important role in cardiovascular risk reduc-
tion in patients scheduled for vascular surgery. Besides their
positive impact on long-term cardiac risk reduction recent
studies have also shown a consistent reduction in perioper-
ative events. The new ESC guidelines grant statins a pivotal
role in the prevention of perioperative cardiac events. After
the release of the ESC guidelines the randomised, placebo-
controlled DECREASE III trial found a significant 47% relative
risk reduction for the endpoint of perioperative myocardial
ischemia and a 53% relative risk reduction for the combined
endpoint of non-fatal myocardial infarction and cardiovas-
cular deaths.2 The numbers needed to treat to prevent these
outcomes were, respectively, 13 and 19. Patients with
symptomatic peripheral arterial disease also benefit from
long-term statin use. Therefore, the preoperative screening
visit should be considered an excellent opportunity not only
for perioperative cardiac risk reduction by statins but also
long-term cardiac risk reduction.Beta-blockers
Since the publication of the POISE study and the subsequent
meta-analysis by Bangalore et al., much debate has been
going on the usefulness and safety of perioperative beta-
blocker therapy.3 Based on current literature, including the
most recent trials, the ESC guideline committee has come
to straight-forward recommendations for perioperative
beta-blocker therapy. Beta-blockers are strongly recom-
mended for patients with high cardiac risk based on
multiple clinical cardiac risk factors and stress-induced
myocardial ischaemia. Furthermore, beta-blocker therapy
is probably reasonable for patients at intermediate risk
scheduled for high-risk and intermediate-risk surgery such
as vascular surgery. Importantly, in patients with an indi-
cation, beta-blockers should be started as early as possible
at a low dose and up-titrated if necessary to achieve
a target heart rate of 60e70 beats per minute. Acute
initiation of high-dose beta-blocker therapy should be
avoided.
Anti-platelet therapy
The role of anti-platelet therapy for the prevention of
perioperative cardiac events remains controversial. The
4 Editorialpossible anti-thrombotic benefits of anti-platelet therapy
on perioperative cardiac outcome should be weighted
against the possibly increased bleeding risk of its use.
However, in general, it is recommended to continue anti-
platelet therapy throughout the perioperative period. Only
in those patients in whom it is anticipated that intra-
operative haemostasis is difficult to control aspirin therapy
should be discontinued.
Conclusion
This editorial is merely a summary of the most important
points of the newESC guidelines for perioperative cardiac risk
reduction. For vascular surgeons, it shouldbe realised that the
preoperative screening of their patients does not only offer
a unique opportunity to modify the perioperative cardiac risk
of their patients. It also provides us a golden opportunity to
modify the long-term cardiac risk of our patients.
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